Drug Profile


Alternative Names: E Keppra; E Keppra Dry syrup 50%; EKeppra; Keppra; Keppra XR; L-059; Levetiracetam IR; Levetiracetam XR; SIB-S1; UCB-059; UCB-22059; UCB-L059

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator UCB
  • Developer Ache Laboratories; GlaxoSmithKline; Otsuka Pharmaceutical; UCB
  • Class Acetamides; Antidementias; Antiepileptic drugs; Neuroprotectants; Pyrrolidinones; Small molecules
  • Mechanism of Action SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy; Myoclonic epilepsies; Partial epilepsies; Tonic-clonic epilepsy
  • Discontinued Anxiety disorders; Neuropathic pain; Parkinsonian disorders

Most Recent Events

  • 30 Apr 2016 UCB Pharma completes a phase I trial in Healthy volunteers in USA (NCT02602860)
  • 01 Apr 2016 UCB completes a phase III trial in Generalised tonic-clonic seizures (Adjunctive treatment; In Children, In adolescents, In adults) in Japan (NCT01398956)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top